• 1. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
• 4. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Aminopyrimidines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Aminopyrimidines and derivatives

2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (CAS No. 543712-91-0): An Overview

2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine, with the CAS number 543712-91-0, is a small molecule compound that has garnered significant attention in the field of medicinal chemistry due to its potential therapeutic applications. This compound belongs to the class of pyrimidine derivatives and is characterized by its unique structural features, including a chlorinated pyrimidine ring and a substituted pyrazole moiety.

The molecular formula of 2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine is C₉H₉ClN₄, and it has a molecular weight of 208.66 g/mol. The compound's structure consists of a pyrimidine ring with a chlorine substituent at the 2-position and an N-linked 5-methylpyrazole moiety at the 4-position. These structural elements contribute to its unique chemical and biological properties, making it an attractive candidate for various pharmaceutical applications.

In recent years, extensive research has been conducted to explore the biological activities and potential therapeutic uses of 2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine. One of the most notable areas of investigation is its anti-inflammatory properties. Studies have shown that this compound can effectively inhibit the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are key mediators in various inflammatory diseases. This makes it a promising candidate for the treatment of conditions such as rheumatoid arthritis, inflammatory bowel disease, and other autoimmune disorders.

Beyond its anti-inflammatory effects, 2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine has also been studied for its potential anticancer properties. Research has demonstrated that this compound can induce apoptosis in cancer cells by modulating key signaling pathways involved in cell survival and proliferation. For instance, it has been shown to inhibit the activation of the PI3K/Akt pathway, which is frequently dysregulated in various types of cancer. These findings suggest that 2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine could be a valuable lead compound for the development of novel anticancer agents.

In addition to its therapeutic potential, 2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine has been evaluated for its pharmacokinetic properties. Studies have shown that it exhibits favorable absorption, distribution, metabolism, and excretion (ADME) characteristics, which are crucial for its clinical development. The compound has good oral bioavailability and demonstrates a reasonable half-life, making it suitable for once-daily dosing regimens. These pharmacokinetic attributes enhance its potential as a drug candidate for various therapeutic applications.

The safety profile of 2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine has also been extensively evaluated in preclinical studies. Toxicity assessments have revealed that it is generally well-tolerated at therapeutic doses, with no significant adverse effects observed in animal models. However, as with any new drug candidate, further clinical trials are necessary to fully evaluate its safety and efficacy in human subjects.

The synthesis of 2-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine has been optimized to improve yield and purity, making it more accessible for research and development purposes. Various synthetic routes have been reported in the literature, including multistep processes involving nucleophilic substitution reactions and coupling reactions. These synthetic methods provide researchers with flexible options to produce this compound on a larger scale for preclinical and clinical studies.

In conclusion, 2-Chloro-N-(5-methyl-1H-pyrazol-3-y l)pyrimidin -4 -amine (CAS No . 543712 -91 -0) is a promising compound with diverse biological activities and potential therapeutic applications. Its anti-inflammatory and anticancer properties, combined with favorable pharmacokinetic characteristics and a good safety profile, make it an attractive candidate for further development in medicinal chemistry. Ongoing research continues to uncover new insights into the mechanisms of action and therapeutic potential of this compound, paving the way for its potential use in treating various diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)